Catalyst
Slingshot members are tracking this event:
Sarepta began recruiting patients for a Phase 3 trial to treat Duchenne muscular dystrophy with its lead product candidate, Eteplirsen
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SRPT |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 03, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Duchenne Muscular Dystrophy, Eteplirsen
